Microbleed and microinfarct detection in amyloid angiopathy: a high-resolution MRI-histopathology study

Susanne J. van Veluw, Andreas Charidimou, Andre J. van der Kouwe, Arne Lauer, Yael D. Reijmer, Isabel Costantino, M. Edip Gürol, Geert Jan Biessels, Matthew P. Frosch, Anand Viswanathan and Steven M. Greenberg

Cerebral amyloid angiopathy is a common neuropathological finding in the ageing human brain, associated with cognitive impairment. Neuroimaging markers of severe cerebral amyloid angiopathy are cortical microbleeds and microinfarcts. These parenchymal brain lesions are considered key contributors to cognitive impairment. Therefore, they are important targets for therapeutic strategies and may serve as surrogate neuroimaging markers in clinical trials. We aimed to gain more insight into the pathological basis of magnetic resonance imaging-defined microbleeds and microinfarcts in cerebral amyloid angiopathy, and to explore the pathological burden that remains undetected, by using high and ultra-high resolution ex vivo magnetic resonance imaging, as well as detailed histological sampling. Brain samples from five cases (mean age 85 ± 6 years) with pathology-proven cerebral amyloid angiopathy and multiple microbleeds on in vivo clinical magnetic resonance imaging were subjected to high-resolution ex vivo 7 T magnetic resonance imaging. On the obtained high-resolution (200 µm isotropic voxels) ex vivo magnetic resonance images, 171 microbleeds were detected compared to 66 microbleeds on the corresponding in vivo magnetic resonance images. Of 13 sampled microbleeds that were matched on histology, five proved to be acute and eight old microhaemorrhages. The iron-positive old microhaemorrhages appeared approximately four times larger on magnetic resonance imaging compared to their size on histology. In addition, 48 microinfarcts were observed on ex vivo magnetic resonance imaging in three out of five cases (two cases exhibited no microinfarcts). None of them were visible on in vivo 1.5 T magnetic resonance imaging after a retrospective analysis. Of nine sampled microinfarcts that were matched on histology, five were confirmed as acute and four as old microinfarcts. Finally, we explored the proportion of microhaemorrhage and microinfarct burden that is beyond the detection limits of ex vivo magnetic resonance imaging, by scanning a smaller sample at ultra-high resolution, followed by serial sectioning. At ultra-high resolution (75 µm isotropic voxels) magnetic resonance imaging we observed an additional 48 microbleeds (compared to high resolution), which proved to correspond to vasculopathic changes (i.e. morphological changes to the small vessels) instead of frank haemorrhages on histology. After assessing the serial sections of this particular sample, no additional haemorrhages were observed that were missed on magnetic resonance imaging. In contrast, nine microinfarcts were found in these sections, of which six were only retrospectively visible at ultra-high resolution. In conclusion, these findings suggest that microbleeds on in vivo magnetic resonance imaging are specific for microhaemorrhages in cerebral amyloid angiopathy, and that increasing the resolution of magnetic resonance imaging results in the detection of more ‘non-haemorrhagic’ pathology. In contrast, the vast majority of microinfarcts currently remain under the detection limits of clinical in vivo magnetic resonance imaging.

1 J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
2 Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
3 Athinoula A. Martinos Center for Biomedical Research, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA

© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Introduction

Sporadic cerebral amyloid angiopathy (CAA) is a common neuropathological finding in the ageing human brain and an important risk factor for cognitive impairment and lobar intracerebral haemorrhage. On autopsy, ~50–80% of brains of patients with dementia have CAA, which is moderate-to-severe in ~30% of the cases (Ellis et al., 1996; Pfeifer et al., 2002). Even in community-dwelling elderly individuals, moderate-to-severe CAA is observed in ~25% of the brains at autopsy (Arvanitakis et al., 2011a; Boyle et al., 2015). Histopathologically, CAA is characterized by the accumulation of amyloid-β in the walls of leptomeningeal and cortical small vessels (Thal et al., 2009). Severe CAA is often accompanied by vasculopathic changes (i.e. morphological changes to the small vessels such as microaneurysms and fibrinoid necrosis) (Love et al., 2014), and multiple cortical parenchymal lesions such as microhaemorrhages and microinfarcts (Haglund et al., 2006; Soontornniyomkij et al., 2010; Kövari et al., 2013; Love et al., 2014). It is believed that these widely distributed lesions in the brain parenchyma contribute to cognitive impairment often observed in patients with CAA (Arvanitakis et al., 2011b; Greenberg et al., 2014). Hence, they are potentially important targets for prevention and therapeutic strategies, and may serve as surrogate neuroimaging markers in clinical trials (Greenberg et al., 2014). However, it remains largely unknown to what extend we are currently capturing the whole burden of microhaemorrhages and microinfarcts on clinical in vivo MRI, which complicates their use in clinical decision-making and therapeutic trials to date.

Currently, cerebral microbleeds (CMBs) are the key neuroimaging manifestations in CAA (Greenberg et al., 2009). A clinical diagnosis of CAA during life relies on the presence of a large intracerebral haemorrhage, or multiple strictly lobar CMBs, visible as small hypointense round or ovoid lesions on T2*-weighted MRI (Knudsen et al., 2001; Martinez-Ramirez et al., 2015). Although it is widely believed that CMBs represent old microhaemorrhages in the parenchyma, the exact underlying pathology of these MRI-defined lesions remains to a large extent unclear, because few studies have directly and systematically verified them with pathology (Shoamanesh et al., 2011).

Moreover, histological observations from such MRI-pathology studies suggest that not only ‘frank’ haemorrhages, but also morphological changes to the small vessels or haemorrhagic microinfarcts may be visible as CMBs on MRI (Fazekas et al., 1999; Schrag et al., 2010; van Veluw et al., 2016). But as these correlation studies were primarily performed in post-mortem human brain tissue, it remains unclear how these findings translate to CMBs visible on in vivo MRI. Throughout this paper we use the term ‘CMB’ for the MRI-defined lesion, and ‘microhaemorrhage’ for the pathological manifestation of an old or acute haemorrhage (based on evidence of intact or degraded erythrocyte extravasation) on histology.

Although microinfarcts have extensively been described in autopsy studies (Haglund et al., 2006; Soontornniyomkij et al., 2010; Kövari et al., 2013), they have long been considered ‘invisible’ on MRI (Smith et al., 2012). It was recently shown that microinfarcts in cortical areas of the brain can be captured in vivo as hyperintense lesions on high resolution T2*-weighted images acquired at 7 T MRI (van Veluw et al., 2013, 2015a). Moreover, it was shown that a subset of these lesions is also visible at 3 T MRI (van Dalen et al., 2015; van Veluw et al., 2015b). However, it remains unclear if microinfarcts can be captured with (1.5 T) MRI scans used in clinical practice.

In this study, we aimed to gain more insight into the pathological basis of MRI-defined CMBs and microinfarcts in the context of CAA and to explore the proportion of the pathological burden that remains undetected. To this end, we performed high and ultra-high resolution ex vivo 7 T MRI and histopathological examination in pathology-proven CAA cases with a high lesion burden on their in vivo MRI.

Material and methods

Cohort description and study design

The overall study design is summarized in Fig. 1. We searched across datasets of the Massachusetts General Hospital for patients seen during the period 1997–2012, aged >55, who underwent both brain MRI and brain autopsy. At autopsy, one hemisphere was formalin-fixed and
subjected to routine neuropathological examination. Patients were selected if they showed pathological evidence of mild, moderate or severe CAA on autopsy and had available in vivo T2*-weighted MRI scans (Martinez-Ramirez et al., 2015). Hence, 45 patients met these criteria. Two experienced raters (S.J.v.V and A.L.) assessed CMBs on the last MRI scan before death [inter-rater reliability was excellent; Intraclass Correlation (ICC) = 0.86], followed by a consensus meeting to obtain definite CMB ratings. Next, to ensure a high lesion yield for ex vivo MRI and subsequent histological examination, patients with >10 lobar CMBs were selected for inclusion in our study. The local institutional review board approved the study and written informed consent was obtained prior to autopsy.

To verify the pathology of magnetic resonance-observed CMBs (Aim 1), we first assessed CMBs on the obtained ex vivo MRI images according to well established rating criteria (Gregoire et al., 2009; Wardlaw et al., 2013), followed by detailed histopathological examination of a representative subset of these lesions. In one case with adequate in vivo MRI scan quality, we were able to match CMBs observed on in vivo MRI to the corresponding ex vivo MRI and histopathology sections (sub-Aim 1 b). Second, we assessed microinfarcts on the same ex vivo MRI images, followed by detailed histopathological examination of a representative subset of these lesions (Aim 2). Finally, we rescanned one smaller sample cut from a slab containing the highest number of magnetic resonance-observed CMBs, with a dedicated ultra-high resolution ex vivo MRI protocol, followed by serial sectioning of the whole tissue. Hence we explored the microvascular abnormalities that are visible at this ultra-high resolution, but remained undetected at high resolution ex vivo MRI and in vivo MRI (Aim 3). Hence, we rescanned one smaller tissue sample, cut from a slab containing the highest number of lesions (based on the high resolution scan), with an ultra-high resolution ex vivo MRI protocol, and followed by serial sectioning of the entire sample.

**Brain tissue**

For each case, four or five formalin-fixed 5–10-mm thick continuous coronal brain slabs were selected from the brain area with the highest burden of CMBs on the last in vivo MRI scan prior to death. For each ex vivo scan session, slabs submerged in 10% formalin were placed in the correct anatomical order in a glass container that fitted in the head coil of the MRI scanner. Care was taken to avoid air bubbles by gently shaking the tissue.

**Ex vivo MRI protocol**

Scans were acquired overnight on a whole-body 7T magnetic resonance Siemens MAGNETOM scanner with a custom built 32-channel head coil. The optimized scan protocol included spoiled gradient echo T2*-weighted (FLASH) and T2-weighted acquisitions. FLASH consisted of multiple gradient echoes (multiple echo times) and multiple flip angles, combined using the FLASH steady-state equation (Fischl et al., 2004; Deoni et al., 2005). T2-weighted volumes were obtained by averaging multiple turbo spin echo (TSE) acquisitions with identical scan parameters. The parameters for the high resolution FLASH acquisitions were as follows: one run each of four flip angles...
(10°, 20°, 30° and 40°), matrix 480 × 480, 384 partitions, voxel size 200 × 200 × 200 μm³, 96 × 96 × 76.8 mm³ volume, repetition time = 20 ms, single echo echo time = 8.67 ms, bandwidth = 180 Hz/px, scan duration 61.26 s, processed to fit proton density, T₁ and T₂⁻, and combined to synthesize the original flip angles from all four scans. The parameters for the high resolution TSE acquisitions were as follows: matrix 330 × 320, 120 partitions, voxel size 300 × 300 × 300 μm³, 99 × 96 × 36 mm³ volume, flip angle = 120°, turbo factor 9, repetition time = 1000 ms, echo time = 63 ms, bandwidth = 401 Hz/px, scan duration 60 min 1 s, with four averages.

**Ex vivo MRI rating and sampling**

One experienced observer (S.J.v.V.) screened the acquired high resolution ex vivo MRI scans for CMBs (intra-rater reliability was excellent; ICC = 0.94) and cortical microinfarcts (intra-rater reliability was excellent; ICC = 0.83), blinded to clinical data and in vivo MRI. CMBs were defined as focal, round or ovoid hypointense lesions on T₂⁻ and T₂*-weighted magnetic resonance images, <10 mm in greatest dimension (measured on T₂⁺), according to well-established rating criteria (Gregoire et al., 2009; Wardlaw et al., 2013). Because T₂⁺-weighted ex vivo MRI is highly susceptible to artefacts caused by remaining air bubbles trapped in sulci and between slabs, the T₂⁻ weighted scan was used to discriminate actual CMBs from such air artefacts. Cortical microinfarcts were defined as focal hyperintense lesions on T₂-weighted MRI, isointense on T₂⁺, <5 mm in greatest dimension, located within the cortical ribbon, according to previously proposed rating criteria (van Veluw et al., 2015a, c). A second observer (A.C.) screened the same ex vivo MRI images to establish inter-rater reliability, which proved to be excellent for CMBs (ICC = 0.80) and good for cortical microinfarcts (ICC = 0.70). Microbleed and microinfarct rating was performed using an in-house developed tool, incorporated in MeVisLab (MeVis Medical Solutions AG, Bremen, Germany).

Next, per case several samples were taken, targeting representative CMBs and microinfarcts for histopathological analysis. These pathological samples measured ~20 × 15 × 5 mm³ to fit a tissue cassette.

**Histopathological analysis**

Samples were dehydrated, embedded in paraffin, and cut in 6-μm thick serial sections on a microtome. Lesion retrieval was guided by the corresponding ex vivo MRI, based on tissue architecture and estimated depth of the lesion within the tissue blocks. At the estimated lesion location, sections were collected on glass slides for standard haematoxylin and eosin staining. Adjacent sections were collected and saved for immunohistochemistry. Next, haematoxylin and eosin sections were matched with the ex vivo MRI scans, to verify retrieval of targeted CMBs and microinfarcts on MRI. If necessary, additional sections were cut at different depths. In case of positive retrieval, adjacent sections were stained for GFAP, amyloid-β, and Perl’s iron. All histopathological findings were independently confirmed by an experienced board-certified neuropathologist (M.P.F.), blinded to MRI findings and clinical data. The neuropathologist scored the lesions for presence of erythrocyte extravasation (indicative of a recent haemorrhagic event), blood-breakdown products (such as haematoxin or haemosiderin, indicative of subacute or old haemorrhages), areas of tissue pallor corresponding to microinfarction, and vasculopathies (i.e. morphological changes to the small vessels, such as fibrin in the vessel wall or microaneurysms).

**Ex vivo MRI—in vivo MRI registration**

In one case, matching of the whole ex vivo scanned brain volume (consisting of four continuous 10-mm thick brain slabs) to the previously obtained in vivo MRI was feasible, based on preservation of the anatomical order of these slabs and availability of a high quality in vivo 3D T₁⁻ weighted 1.5 T MRI for reliable registration. The interval between last in vivo MRI and death in this case was 1 year and 14 days. Registration was performed using manual and affine registration approaches contained in the Freesurfer toolbox (surfer.nmr.mgh.harvard.edu) (Fischl, 2012) based on landmarks in the relevant cortical ribbon.

**Exploratory ultra-high resolution ex vivo MRI and histopathology**

To explore the pathological burden that remained undetected at high resolution ex vivo MRI (and clinical resolution in vivo MRI), a small area from one of the slabs containing a high lesion burden was selected and scanned with a dedicated ultra-high resolution protocol. Subsequently the sample was cut into serial sections as a whole for detailed histopathological analysis. For this exploratory study, one area with the highest number of CMBs on the obtained high resolution ex vivo MRI was chosen and sampled to fit in a 50 ml falcon tube, submerged in Fomblin® (Solvay Solexis). The tube was placed in a custom built (four-turn) solenoid coil (with an inner diameter of 30 mm), and scanned for ~39 h using the 7 T MRI scanner described above. The parameters for the ultra-high resolution FLASH acquisitions were as follows: four runs each of four flip angles (10°, 20°, 30° and 40°), matrix 448 × 896, 352 partitions, voxel size 75 × 75 × 75 μm³, 33.6 × 67.2 × 26.4 mm³ volume, repetition time = 45 ms, single echo echo time = 15.8 ms, bandwidth = 70 Hz/px, scan duration 1 h 58 min 9 s, processed to fit proton density, T₁ and T₂⁻ and combined to synthesize the original flip angles from all 16 scans. The parameters for the ultra-high resolution TSE acquisitions were as follows: matrix 320 × 512, 128 partitions, voxel size 100 × 100 × 100 μm³, 32 × 51.2 × 12.8 mm³ volume, flip angle = 120°, turbo factor = 9, repetition...
**Table 1 Case characteristics and ex vivo MRI findings**

<table>
<thead>
<tr>
<th>Case ID</th>
<th>Sex</th>
<th>Lobar CMB number on in vivo MRI (field strength)</th>
<th>Age at death (years)</th>
<th>Medical history</th>
<th>Cause of death</th>
<th>MRI-death interval</th>
<th>Slabs subjected to ex vivo MRI (7 T)</th>
<th>Cortical CMIs on ex vivo MRI (7 T)</th>
<th>Cortical CMIs on ex vivo MRI (7 T)</th>
<th>General pathology findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>12 (1.5 T)</td>
<td>7</td>
<td>Dementia</td>
<td>Aspiration bronchopneumonia</td>
<td>1 y</td>
<td>4 R frontal</td>
<td>30</td>
<td>0</td>
<td>Mild CAA (VS 2); AD (BB III); LBD (B V); moderate hypertensive CVD</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>70 (1.5 T)</td>
<td>18</td>
<td>Dementia, left thalamic stroke, CAA, hypertension</td>
<td>Unknown</td>
<td>7 d</td>
<td>5 L occipital</td>
<td>72</td>
<td>17</td>
<td>Moderate CAA (VS 3); AD (BB III); moderate hypertensive CVD</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>44 (1.5 T)</td>
<td>11</td>
<td>Dementia, CAA with prior intracerebral haemorrhages</td>
<td>Intracerebral haemorrhage</td>
<td>2 y</td>
<td>5 R occipital</td>
<td>19</td>
<td>27</td>
<td>Severe CAA (VS 4); AD (BB IV); primary intracerebral haemorrhage; moderate hypertensive CVD</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>31 (1.5 T)</td>
<td>5</td>
<td>Dementia</td>
<td>Unknown</td>
<td>6 y</td>
<td>5 R frontal</td>
<td>25</td>
<td>4</td>
<td>Moderate CAA (VS 3); AD (BB VI); severe hypertensive CVD</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>42 (3 T)</td>
<td>25</td>
<td>Dementia</td>
<td>Unknown</td>
<td>4 y</td>
<td>5 R occipital</td>
<td>25</td>
<td>0</td>
<td>Modest hypertensive CVD</td>
</tr>
</tbody>
</table>

*Extracted from medical records.

**Results**

**Histopathology of ex vivo magnetic resonance-observed cerebral microbleeds**

Brain slabs from five cases (mean age 85 ± 6 years) were selected for ex vivo MRI scanning (Fig. 1). Case characteristics are presented in Table 1. Other in vivo MRI findings can be found in Supplementary Table 1. In total, 171 CMIs were observed on ex vivo MRI of the examined slabs, compared to 146 CMIs on the corresponding in vivo MRI scans of these cases. Interestingly, in one case that underwent 3 T susceptibility-weighted MRI, the same number of CMIs was observed both ex vivo as well as in vivo (Table 1).

All CMIs were sampled for histopathological examination. To infer the cortical ribbon, 20 CMIs were observed on ex vivo MRI, were located in the white matter of the corresponding in vivo clinical MRI scans of the same area. In total, 20 CMIs could be retrieved on the corresponding haematoxylin-eosin sections, whereas seven were missed because of MRI-histopathology mismatching. Eight represented old or subacute microhaemorrhages characterized by iron-positive haemosiderin deposits with or without haematoidin (Fig. 2). They appeared more than four-times larger on high-resolution T2*-weighted MRI (mean size 1.4 ± 0.6 mm) compared to their actual size on the haematoxylin and eosin section (mean size 0.3 ± 0.2 mm; paired samples t-test 7.5, P < 0.001). Five represented acute microhaemorrhages characterized by a focal accumulation of intact erythrocytes (Fig. 2). One acute microhaemorrhage was negative for iron staining, three were accompanied by only a few iron-positive haemosiderin deposits, and one demonstrated many iron-positive haemosiderin deposits, suggesting that the involved vessel had ruptured before. The size of these acute microhaemorrhages was similar to their actual size on the haematoxylin and eosin sections (mean size 0.9 ± 0.6 mm; paired samples t-test 2.8, P = 0.048). The obtained ultra-high resolution MRI scans (dwell time = 1500 ms, echo time = 7 ms, bandwidth = 148 Hz/pixel, time = 1500 ms, echo time = 7 ms, bandwidth = 148 Hz/pixel, time = 1500 ms, echo time = 7 ms, bandwidth = 148 Hz/pixel) could be found in the Supplementary material. The obtained ultra-high resolution MRI scans could be found in the Supplementary material. The obtained ultra-high resolution MRI scans could be found in the Supplementary material. The obtained ultra-high resolution MRI scans could be found in the Supplementary material.
Histopathology of in vivo magnetic resonance-observed cerebral microbleeds

We were able to register the ex vivo 7 T MRI to the previously acquired in vivo 1.5 T MRI in Case 1, allowing a direct validation of in vivo observed CMBs. In this volume, 30 CMBs were visible on ex vivo MRI, compared to seven on the corresponding in vivo T2*-weighted MRI. All seven in vivo observed CMBs could be matched with CMBs on ex vivo MRI (Fig. 3). Three in vivo observed CMBs were sampled as part of Aim 1 (see above), and proved to be old microhaemorrhages on microscopy. Of note, these three old microhaemorrhages measured <300 μm on the haematoxylin and eosin section. No microinfarcts were observed in this case, or on ex vivo MRI, or on in vivo MRI.

Histopathology of ex vivo magnetic resonance-observed microinfarcts

Aim 2

A total number of 48 cortical microinfarcts were present on ex vivo MRI of the examined slabs of three of the five cases. In two cases we did not observe any microinfarcts on ex vivo MRI. None of the cortical microinfarcts were retrospectively visible on the corresponding clinical low resolution in vivo fluid-attenuated inversion recovery (FLAIR) or T1-weighted MRI scans of these cases. In terms of their spatial distribution, CMBs and microinfarcts did not co-localize on ex vivo MRI. Microinfarcts, but not CMBs, tended to cluster. In total 10 cortical microinfarcts—observed on ex vivo MRI—were sampled for histopathological examination. Nine of 10 microinfarcts could be retrieved on the corresponding haematoxylin and eosin sections. Four represented chronic microinfarcts characterized by pallor, tissue loss, and gliosis (confirmed by GFAP staining) (Fig. 4). Five represented acute microinfarcts characterized by tissue pallor, and ischaemic or shrunken neurons (Fig. 4). None of the microinfarcts were positive for iron. The size of the microinfarcts on T2*-weighted MRI (mean size 1.5 ± 1.0 mm) was similar to their actual size on the haematoxylin and eosin section (mean size 1.0 ± 0.8 mm; paired samples t-test 1.4, P = 0.218). It should be noted that four of five acute microinfarcts were observed in a case that also had a larger cortical intracerebral haemorrhage in non-adjacent areas. Hence, it cannot be excluded that these microinfarcts were related to the larger event.
Exploratory ultra-high resolution ex vivo MRI

Aim 3

To explore the pathological burden that remained undetected at high resolution ex vivo MRI (and clinical resolution in vivo MRI), we subjected a smaller sample from Case 2 (which was subsequently cut into serial sections) to an ultra-high resolution scan protocol. This chosen region of interest contained 24 CMBs as detected on high resolution (200 μm³ T₂*-weighted) ex vivo MRI. Four CMBs were located at the borders of the processed tissue blocks and could therefore not reliably be assessed on histology, leaving 20 CMBs for histopathological examination. Due to serial sectioning all 20 CMBs were retrieved on histology. Eighteen of 20 CMBs were classified as either acute or old microhaemorrhages upon examination of the histopathologic sections, whereas two CMBs corresponded to vasculopathies (i.e. morphological changes to the vessels without parenchymal damage). This resulted in a positive predictive value of 90% (95% CI 0.68–0.99) for CMBs detected at 200 μm³ T₂*-weighted 7 T MRI.

On the ultra-high resolution (75 μm³ T₂*-weighted) ex vivo MRI an additional 48 smaller hypointense cortical lesions were identified in the same volume, which were not identified as CMBs on the corresponding high resolution ex vivo MRI. Eleven of them had a round or ovoid shape, and hence were considered ‘typical’ (although very small) CMBs, whereas 31 had a more vessel-like and six an irregular appearance, hence considered ‘atypical’ CMBs. Twenty-seven of the 48 additional hypointense lesions could reliably be identified on histopathology, of which 20 (74.1%) corresponded to vasculopathies (Fig. 5), one to a haemorrhagic microinfarct, and only six (22.2%) to actual haemorrhages. On histopathology, such vasculopathies were not found in CMB-negative areas.

We also evaluated the sensitivity of high versus ultra-high resolution ex vivo MRI for microinfarct detection. The same volume contained two cortical microinfarcts as detected on high resolution (300 μm³ T₂-weighted) ex vivo MRI, which were both histologically confirmed. On the ultra-high resolution (100 μm³ T₂-weighted) ex vivo MRI, no additional microinfarcts were observed. After screening all obtained serial histological sections from this particular sample, however, nine microinfarcts were found on...
microscopic examination. Six were in retrospect visible at the ultra-high resolution $T_2$-weighted MRI scan only (Fig. 5), whereas three were too small to be visible on MRI (mean size on haematoxylin and eosin sections $0.2 \pm 0.1 \text{mm}$). Noteworthy, four microinfarcts on pathology were accompanied by several haemosiderin deposits, and hence interpreted as haemorrhagic microinfarcts. Their appearance on MRI was either hypointense or inhomogeneous (partly hypointense/hyperintense).

**Discussion**

This study aimed to gain more insight in the pathological basis of MRI-defined CMBs and microinfarcts, in the context of CAA and to explore the pathological burden that remains undetected. Our combined *in vivo-*ex *vivo*-histopathology approach resulted in several key new insights: (i) lobar CMBs on clinical *in vivo* MRI in patients with CAA are specific for haemorrhagic pathology; (ii) although high resolution (200$\mu$m isotropic resolution) *ex vivo* MRI was able to detect additional CMBs beyond regular clinical resolution *in vivo* MRI, further increased spatial resolution (up to 75$\mu$m isotropic) resulted in the detection of more ‘non-haemorrhagic’ CAA pathology (i.e. vasculopathies). These vasculopathies appeared as CMBs on *ex vivo* MRI and hence reduced specificity for the detection of ‘frank’ haemorrhages at this resolution; and (iii) in contrast to CMBs, the vast majority of microinfarcts currently remain under the detection limits of clinical *in vivo* MRI and even high resolution *ex vivo* MRI. Hence, the sensitivity for microinfarct detection does benefit substantially from an increased spatial resolution.

Our findings suggest that cortical CMBs on MRI in patients with pathology-proven CAA correspond well to ‘frank’ haemorrhages. All 13 retrieved CMBs (Aim 1) proved to be either acute or old microhaemorrhages (based on evidence of extravasations of intact or degraded erythrocytes on histopathology). Seven CMBs could not be retrieved on histology, most likely due to mismatching between the MRI scans and the histology sections. It cannot be excluded, however, that these missed lesions may have...
represented other types of pathology or abnormalities related to post-mortem imaging (e.g. post-mortem thrombi in penetrating vessels or trapped air bubbles). Importantly, the fact that serial sectioning (in the context of Aim 3) did reveal all targeted CMBs \((n = 20)\) on histology, supports the interpretation that the seven missing CMBs in the analysis of Aim 1 were indeed caused by mismatching problems and did not in fact represent false-positive CMBs. Being able to compare these additional 20 CMBs to the histopathology-based standard (provided by the serial sections) resulted in a positive predictive value of 90\% (only two CMBs did not represent frank haemorrhages, but vasculopathies). This underlines the high specificity of CMBs to represent actual haemorrhagic pathology. Interestingly, by lining up the \textit{ex vivo} MRI with \textit{in vivo} MRI in one case, we found that even very small \((< 300 \mu m)\) old microhaemorrhages on pathology can still be detected \textit{in vivo} MRI. Furthermore, the observation that old—iron-positive—microhaemorrhages bloom more than acute—iron-negative—microhaemorrhages is in line with previous observations (Schrag \textit{et al.}, 2010; van Veluw \textit{et al.}, 2016). It has also been suggested that smaller microhaemorrhages bloom more than larger (Schrag \textit{et al.}, 2010), which may also explain our current and previous

\begin{figure*}[h]
\centering
\includegraphics[width=\textwidth]{figure5.png}
\caption{Exploratory ultra-high resolution \textit{ex vivo} MRI. Ultra-high resolution \textit{ex vivo} magnetic resonance images of a sampled brain area from Case 2 reveal striking detail of CAA-related pathology. \textit{Top row}: Here we show three representative microbleeds that were identified on the ultra-high resolution \(T_2^*\)-weighted \textit{ex vivo} magnetic resonance image (voxel size 75 \(\mu m^3\)), of which the larger one (broken arrow) was also visible at the corresponding high resolution \(T_2^*\)-weighted \textit{ex vivo} magnetic resonance image (voxel size 200 \(\mu m^3\)) (\textit{A}). This microbleed corresponded to a recent microhaemorrhage on haematoxylin and eosin, characterized by a focal accumulation of intact erythrocytes (broken arrow; \textit{B}). The hypointense lesions (arrows) that were not rated as microbleeds at high-resolution \(T_2^*\)-weighted \textit{ex vivo} MRI, proved to be vasculopathies on haematoxylin and eosin, without parenchymal tissue injury (arrows; \textit{B}, enlarged in \textit{C} and \textit{D}). The vasculopathy in \textit{C} resembles an occluded vessel containing fibrin deposits. The vasculopathy in \textit{D} resembles a microaneurysm. \textit{Bottom row}: Here we show a microinfarct that was identified on microscopic examination of the serial histological sections taken from this sample (\textit{F}), and retrospectively could be identified as a hyperintense lesion on the corresponding ultra-high resolution \(T_2^*\)-weighted \textit{ex vivo} magnetic resonance image (voxel size 100 \(\mu m^3\)) (\textit{E}), whereas it escaped detection at high-resolution \(T_2\)-weighted \textit{ex vivo} MRI (voxel size 300 \(\mu m^3\)). Note the vessel at the centre of this microinfarct (broken arrow in \textit{F}), which can be distinguished on the scan (hypointense structure within the hyperintense lesion in \textit{E}).}
\end{figure*}
observations, as old microhaemorrhages were generally smaller on histology than the acute ones. Previous studies have demonstrated that it is possible to quantify iron content of individual lesions on MRI (Klohs et al., 2011). This may be an interesting avenue to help discriminate old from acute microhaemorrhages in vivo. Moreover, we noticed that acute haemorrhages sometimes generate heterogeneous signal intensities on MRI when they consist of partly intact and partly lysed erythrocytes (Fig. 5; van Veluw et al., 2016). This could also potentially—when not limited by spatial resolution—help discriminate acute from old bleeding events in vivo.

In this study, on average 2.5-times more CMBs were identified on high-resolution ex vivo 7T MRI compared to clinical in vivo MRI. Interestingly, such an enhanced detection was not observed for the one individual who underwent 3T susceptibility-weighted MRI in vivo. This suggests, and confirms previous observations (Nandigam et al., 2009), that 3T MRI is more sensitive for CMB detection compared to lower resolution 1.5T MRI. It cannot be excluded that a number of CMBs may have occurred in the interval between last MRI and death. However, this seems unlikely because in one patient (Case 2; Table 1) who had her last MRI 7 days before she died, ex vivo MRI detected four-times more CMBs than in vivo MRI. Considering it unlikely that the extra CMBs occurred within those 7 days, it underlines the higher sensitivity of ex vivo 7T MRI for the detection of CMBs compared to clinical in vivo MRI. This is in line with previous studies, demonstrating that 7T in vivo MRI results in increased detection of CMBs compared to 1.5T MRI (Conijn et al., 2011; Ni et al., 2015) and 3T MRI (Brundel et al., 2012). This higher sensitivity seems to be mainly driven by the higher spatial resolution of 7T MRI and different image contrast, compared to conventional MRI (Brundel et al., 2012; van Veluw et al., 2014). Markedly, all ex vivo magnetic resonance-observed CMBs in this study were located in the cortical ribbon, which is consistent with a previous high-resolution ex vivo (van Veluw et al., 2016) and in vivo 7T MRI study (Ni et al., 2015).

We found that further increasing the spatial resolution to 75 µm³ using ultra-high resolution ex vivo MRI results in the detection of other CAA-related non-haemorrhagic pathologies. This is in line with previous ex vivo MRI-histopathology correlation studies in the context of CAA, which suggested that not all CMBs represent actual haemorrhages, but that some of them may represent non-haemorrhagic vasculopathies (Schrag et al., 2010; Fisher, 2014; van Veluw et al., 2016). In one of our recent ex vivo 7T MRI-histopathology studies in cases with severe CAA, we found that 4 of 17 cortical CMBs represented vasculopathies instead of haemorrhages (van Veluw et al., 2016). Vasculopathies are frequently observed in the context of more severe CAA, and may represent the vessels that are most likely to bleed upon disease progression (Vonsattel et al., 1991; Love et al., 2014). Hence, these vessels are interesting targets to get to the mechanisms underlying haemorrhage formation in CAA. Ultra-high resolution MRI provides a unique tool to accurately target these lesions for further detailed histopathological analysis, and should be used in future studies. For example, determining absence or presence of vascular amyloid-β in such vessels would provide invaluable insight into the role of vascular amyloid-β in haemorrhage formation.

In contrast to CMBs, clinical in vivo MRI highly underestimates the detection of cortical microinfarcts, as none of the microinfarcts observed on ex vivo MRI proved to be visible on in vivo 1.5T MRI. Previous studies have shown, however, that increasing spatial resolution, either by means of in vivo 7T MRI (van Veluw et al., 2013; van Rooden et al., 2014; Dieleman et al., 2016) or ex vivo MRI (van Veluw et al., 2015a), strongly increases sensitivity for microinfarct detection. Our findings showed that cortical microinfarcts have a similar size on ex vivo MRI compared to their size on histology. The improved sensitivity of high resolution ex vivo or in vivo MRI for microinfarct detection (as compared to clinical in vivo MRI) seems largely driven by a higher spatial resolution. In our previous work, we suggested to use T1-weighted MRI for the detection of microinfarcts on clinical 3T MRI scans (van Veluw et al., 2015b, c), as these images both exhibit high spatial resolution and great contrast between grey and white matter (unlike most clinically-used FLAIR scans). The clinical in vivo 1.5T MRI protocol that most subjects in this study underwent included a poor quality T1-weighted sequence, which explains why no microinfarcts could retrospectively be observed on in vivo MRI here. One patient who underwent 3T MRI in vivo did not show any microinfarcts ex vivo. Hence, we could unfortunately not verify enhanced detection of microinfarcts at 3T (as opposed to 1.5T) in this case.

This is one of the first studies investigating the co-occurrence of CMBs and microinfarcts on MRI in the context of CAA. We found no topographical co-localization of CMBs and microinfarcts. Moreover, microinfarcts were only found in the cases with more severe CAA, which is consistent with previous studies (Haglund et al., 2006; Soontornniyomkij et al., 2010; Kövari et al., 2013). This suggests that microinfarcts are an expression of more severe CAA burden, and may also point to different mechanisms underlying microhaemorrhage and microinfarct formation. Although microhaemorrhages are considered to be the result of severe CAA as well (Vonsattel et al., 1991; Love et al., 2014), the positive association between multiple CMBs on MRI and more severe CAA on pathology has not convincingly been demonstrated yet (Charidimou et al., 2016). Likewise, although all our cases had >10 CMBs on in vivo MRI, only two cases proved to have the highest CAA severity score (according to the Vonsattel criteria) on neuropathological examination (Table 1). This raises intriguing questions about the direct link between CAA severity and microhaemorrhage formation at the single vessel level, a topic for future studies. The observation of haemorrhagic microinfarcts in this study...
and in previous studies is of interest as it suggests different mechanisms (both erythrocyte extravasation and infarction) associated with the same vessel.

The strength of this study is that we combined in vivo MRI with ex vivo MRI and in-depth histopathology. A clear limitation was the availability of only a small number of cases. However, using high quality 7 T MRI scan protocols we were able to assess both high numbers of CMBs and microinfarcts on MRI in the context of CAA, investigate their underlying pathology, and to translate our findings to clinical in vivo MRI. It should be noted that the implications derived from these findings solely relate to cortical microvascular lesions. As the slabs subjected to ex vivo MRI in this study did not contain subcortical areas (e.g. basal ganglia), other studies are needed to further investigate the pathology of CMBs in deep areas of the brain, as it has been suggested that they are less specific for haemorrhagic pathology, and they may also be the result of calcifications or ischaemic tissue injury (Janaway et al., 2014).

Also, because we purposefully included cases with >10 CMBs (to ensure a high lesion yield on ex vivo MRI and histopathology), this may have led to an underestimation of the lesion burden that goes undetected on MRI. Future studies should look at lesion burden on pathology in cases with no visible CMBs on in vivo MRI. Furthermore, it remains to be seen how our findings translate to different study samples and disease settings (e.g. hypertension, large intracerebral haemorrhages). Finally, unfortunately most patients underwent relatively low quality in vivo 1.5 T MRI, which is not uncommon in clinical practice. Hence, registration of ex vivo MRI to in vivo was only possible in one case. It would be of interest to replicate this in larger numbers of cases, but the availability of datasets including both high quality in vivo MRI scans and subsequent brain autopsy to date is very limited.

Conclusions

The findings of this qualitative in vivo–ex vivo–histopathology study suggest that current in vivo CMB detection in patients with CAA is rather specific for haemorrhages and that increasing resolution to ultra-high levels ($<75 \, \mu\text{m}^3$) results in a drop of specificity due to the detection of more non-haemorrhagic pathology. With respect to microinfarcts, the majority currently escapes detection on clinical in vivo and ex vivo MRI. Increasing MRI field strength and spatial resolution improves the detection of microinfarcts. Ultra-high resolution ex vivo MRI appeared to be a powerful tool to study microvascular pathology in CAA at a detailed level, which may aid in unravelling exact mechanisms leading to haemorrhagic and ischaemic tissue injury in this disease. Finally, CMBs and microinfarcts appear to be the most numerous markers of focal haemorrhage and focal ischaemic injury in small vessel diseases (in particular CAA), and therefore are important candidate biomarkers for clinical trials. Our data show that while we are approaching sensitive and specific methods for imaging CMBs in vivo, we are not yet for microinfarcts.

Acknowledgements

The authors would like to thank Thijs van Harten for his help with ex vivo to in vivo MRI registration.

Funding

This work was supported by an Alzheimer Nederland fellowship [WE 15-2013-07] and a Van Leersum grant of the Royal Dutch Academy of Sciences [2467-VLB-519] to S.J.v.V., an NIH grant [R21AG046657] to A.J.v.d.K., a VIDI grant from ZonMw, The Netherlands Organization for Health Research and Development [91711384] to G.J.B., NIH grants [R01AG047795], [P50AG05134], and [K23AG028726] to A.V., and an NIH grant [R01AG26484] to A.V. and S.M.G.

Supplementary material

Supplementary material is available at Brain online.

References


